Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes

Diabetes

Volumn 51, Issue 12, 2002, Pages 3479-3485

  Hällsten, Kirsti ^a   Virtanen, Kirsi A ^a   Lönnqvist, Fredrik ^b   Sipilä, Hannu ^a   Oksanen, Airi ^a   Viljanen, Tapio ^a   Rönnemaa, Tapani ^a   Viikari, Jorma ^a   Knuuti, Juhani ^a   Nuutila, Pirjo ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; INSULIN; METFORMIN; PLACEBO; ROSIGLITAZONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXERCISE; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0036895990     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.12.3479     Document Type: Article

References (56)

1. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176, 2000
2. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP: The effect of insulin on the disposal of intravenous glucose: Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30:1000-1007, 1981
3. Nuutila P, Knuuti MJ, Raitakari M, Ruotsalainen U, Teräs M, Voipio-Pulkki LM, Haaparanta M, Solin O, Wegelius U, Yki-Järvinen H: Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans. Am J Physiol 267:E941-E946, 1994
4. Laine H, Yki-Järvinen H, Kirvelä O, Tolvanen T, Raitakari M, Solin O, Haaparanta M, Knuuti J, Nuutila P: Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity. J Clin Invest 101:1156-1162, 1998
5. Utriainen T, Takala T, Luotolahti M, Rönnemaa T, Laine H, Ruotsalainen U, Haaparanta M, Nuutila P, Yki-Järvinen H: Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia 41:555-559, 1998
6. Day C: Thiazolidinediones: A new class of antidiabetic drugs. Diabet Med 16:179-192, 1999
7. Balfour JA, Plosker GL: Rosiglitazone. Drugs 57:921-930, 1999
8. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872, 1998
9. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI: Mechanism of troglitazone action in type 2 diabetes. Diabetes 49:827-831, 2000
10. Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR, Kahn BB: Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110β protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 51:443-448, 2002
11. Bjornholm M, Kawano Y, Lehtihet M, Zierath JR: Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 46:524-527, 1997
12. Kim YB, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB: Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 104:733-741, 1999
13. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee VK, O'Rahilly S: Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153, 1997
14. Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ, Kirkham DM, Lister CA, Smith SA: Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes: Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes 44:1087-1092, 1995
15. Patel J, Anderson RJ, Rappaport EB: Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1:165-172, 1999
16. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802, 2002
17. DeFronzo RA, Barzilai N, Simonson DC: Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 73:1294-1301, 1991
18. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063-2069, 2000
19. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554, 1995
20. Cusi K, Consoli A, DeFronzo RA: Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:4059-4067, 1996
21. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, Ventura MM, Santeusanio F, Brunetti P, Bolli GB: Acute antihyperglycemic mechanisms of metformin in NIDDM: Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 43:920-928, 1994
22. Widen EI, Eriksson JG, Groop LC: Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 41:354-358, 1992
23. Ploug T, van Deurs B, Ai H, Cushman SW, Ralston E: Analysis of GLUT4 distribution in whole skeletal muscle fibers: Identification of distinct storage compartments that are recruited by insulin and muscle contractions. J Cell Biol 142:1429-1446, 1998
24. Hayashi T, Hirshman MF, Kurth EJ, Winder WW, Goodyear LJ: Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 47:1369-1373, 1998
25. Sherwood DJ, Dufresne SD, Markuns JF, Cheatham B, Moller DE, Aronson D, Goodyear LJ: Differential regulation of MAP kinase, p70(S6K), and Akt by contraction and insulin in rat skeletal muscle. Am J Physiol 276:E870-E878, 1999
26. 18F]fluoro-deoxy-glucose, and positron emission tomography. Diabetes 49:1084-1091, 2000
27. Peltoniemi P, Yki-Järvinen H, Oikonen V, Oksanen A, Takala TO, Rönnemaa T, Erkinjuntti M, Knuuti MJ, Nuutila P: Resistance to exercise-induced increase in glucose uptake during hyperinsulinemia in insulin-resistant skeletal muscle of patients with type 1 diabetes. Diabetes 50:1371-1377, 2001
28. Nuutila P, Raitakari M, Laine H, Kirvelä O, Takala T, Utriainen T, Mäkimattila S, Pitkänen OP, Ruotsalainen U, Iida H, Knuuti J, Yki-Järvinen H: Role of blood flow in regulating insulin-stimulated glucose uptake in humans: Studies using bradykinin, [15O]water, and [18F]fluoro-deoxyglucose and positron emission tomography. J Clin Invest 97:1741-1747, 1996
29. Ruotsalainen U, Raitakari M, Nuutila P, Oikonen V, Sipilä H, Teräs M, Knuuti MJ, Bloomfield PM, Iida H: Quantitative blood flow measurement of skeletal muscle using oxygen-15-water and PET. J Nucl Med 38:314-319, 1997
30. Peltoniemi P, Lönnroth P, Laine H, Oikonen V, Tolvanen T, Grönroos T, Strindberg L, Knuuti J, Nuutila P: Lumped constant for [(18)F]fluorode-oxyglucose in skeletal muscles of obese and nonobese humans. Am J Physiol Endocrinol Metab 279:E1122-E1130, 2000
31. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553, 1998
32. Strijckmans K, Vandecasteele C, Sambre J: Production and quality control of 15O2 and C15O2 for medical use. Int J Appl Radial Isot 36:279-283, 1985
33. Sipilä HT, Clark JC, Peltola O, Teräs M: An automatic [15O]H2O production system for heart and brain studies. J Labelled Comp Radiopharm 44 (Suppl. 1):S1066-S1068, 2001
34. Hamacher K, Coenen HH, Stocklin G: Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27:235-238, 1986
35. Alenius S, Ruotsalainen U: Bayesian image reconstruction for emission tomography based on median root prior. Eur J Nucl Med 24:258-265, 1997
36. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M: The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897-916, 1977
37. Patlak CS, Blasberg RG: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: Generalizations. J Cereb Blood Flow Metab 5:584-590, 1985
38. Nuutila P, Koivisto VA, Knuuti J, Ruotsalainen U, Teras M, Haaparanta M, Bergman J, Solin O, Voipio-Pulkki LM, Wegelius U, et al: Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 89:1767-1774, 1992
39. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
40. Del Prato S, Enzi G, Vigili dK, Lisato G, Riccio A, Maifreni L, Iori E, Zurlo F, Sergi G, Tiengo A: Insulin regulation of glucose and lipid metabolism in massive obesity. Diabetologia 33:228-236, 1990
41. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW: A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-1210, 1994
42. Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S, Henry RR: Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 51:30-36, 2002
43. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA: Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219, 2001
44. Galuska D, Nolte LA, Zierath JR, Wallberg-Henriksson H: Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia 37:826-832, 1994
45. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001
46. Wu MS, Johnston P, Sheu WH, Hollenbeck CB, Jeng CY, Goldfine ID, Chen YD, Reaven GM: Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 13:1-8, 1990
47. Kelley DE, Williams KV, Price JC, Goodpaster B: Determination of the lumped constant for [18F] fluorodeoxyglucose in human skeletal muscle. J Nucl Med 40:1798-1804, 1999
48. Utriainen T, Lovisatti S, Mäkimattila S, Bertoldo A, Weintraub S, DeFronzo R, Cobelli C, Yki-Järvinen H: Direct measurement of the lumped constant for 2-deoxy-[1-(14)C]glucose in vivo in human skeletal muscle. Am J Physiol Endocrinol Metab 279:E228-E233, 2000
49. DeFronzo RA, Ferrannini E, Sato Y, Felig P, Wahren J: Synergistic interaction between exercise and insulin on peripheral glucose uptake. J Clin Invest 68:1468-1474, 1981
50. Hevener AL, Reichart D, Olefsky J: Exercise and thiazolidinedione therapy normalize insulin action in the obese Zucker fatty rat. Diabetes 49:2154-2159, 2000
51. Yakubu-Madus FE, Stephens TW, Johnson WT: Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione. Diabetes Obes Metab 2:155-163, 2000
52. Racette SB, Davis AO, McGill JB, Klein S: Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus. Metabolism 51:169-174, 2002
53. Mäkimattila S, Virkamäki A, Groop PH, Cockcroft J, Utriainen T, Fagerudd J, Yki-Järvinen H: Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation 94:1276-1282, 1996
54. Laakso M, Edelman SV, Brechtel G, Baron AD: Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: A novel mechanism for insulin resistance. J Clin Invest 85:1844-1852, 1990
55. Laakso M, Edelman SV, Brechtel G, Baron AD: Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 41:1076-1083, 1992
56. Vehkavaara S, Mäkimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Järvinen H: Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 20:545-550, 2000